Novavax may be years away from a potential approval of its RSV vaccine, but on the company’s recent year-end conference call, executives talked up the candidate’s commercial appeal and the steps they’re taking now to prepare for a possible rollout.
{iframe}https://www.fiercepharma.com/vaccines/novavax-details-pre-commercialization-activities-1-5b-sales-target-rsv{/iframe}